Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Diagnostic Antibodies and Proteins Detected with DNA Nanomachines

By LabMedica International staff writers
Posted on 27 Oct 2015
A nanoscale machine composed of synthetic DNA can be used for the rapid, sensitive and low-cost diagnosis of many infectious and autoimmune diseases, including human immunodeficiency virus (HIV) and rheumatoid arthritis (RA). More...


A versatile platform for the one-step fluorescence detection of both monovalent and multivalent proteins has been developed and is based on a conformation-switching stem-loop DNA scaffold that presents a small-molecule, polypeptide, or nucleic-acid recognition element on each of its two stem strands.

Scientists at the University of Rome Tor Vergata (Italy) working with their North American colleagues designed and synthetized a nanometer-scale DNA "machine" whose customized modifications enable it to recognize a specific target antibody. Their new approach promises to support the development of rapid, low-cost antibody detection at the point-of-care, eliminating the treatment initiation delays and increasing healthcare costs associated with current techniques. The protein-targeting sensor is composed of a fluorophore/quencher-modified DNA stem–loop system containing two single-stranded tails. To create a target-responsive sensor, these tails are hybridized with DNAs conjugated to an appropriate recognition element.

The binding of the antibody to the DNA machine causes a structural change or switch, which generates a light signal. The sensor does not need to be chemically activated and is rapid, acting within five minutes, enabling the targeted antibodies to be easily detected, even in complex clinical samples such as blood serum. The versatility of the platform was demonstrated by detecting five bivalent proteins (four antibodies and the chemokine platelet-derived growth factor) and two monovalent proteins (a Fab fragment and the transcription factor TATA Box Binding Protein (TBP) with low nanomolar detection limits and no detectable cross-reactivity.

Francesco Ricci, PhD, a professor and senior coauthor of the study, said, “One of the advantages of our approach is that it is highly versatile. This DNA nanomachine can be in fact custom-modified so that it can detect a huge range of antibodies; this makes our platform adaptable for many different diseases.” The materials needed for one assay cost about USD 0.15, making the approach very competitive in comparison with other quantitative approaches. The study was published on September 4, 2015, in the journal Angewandte Chemie.

Related Links:

University of Rome Tor Vergata



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.